Your browser doesn't support javascript.
loading
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Guillo, Lucas; Savoye, Guillaume; Amiot, Aurélien; Gilletta, Cyrielle; Nachury, Maria; Dib, Nina; Bourreille, Arnaud; Roblin, Xavier; Caillo, Ludovic; Allez, Matthieu; Picon, Laurence; Hébuterne, Xavier; Seksik, Philippe; Chupin, Antoine; Buisson, Anthony; Brixi, Hédia; Altwegg, Romain; Simon, Marion; Amil, Morgane; Laharie, David; Bouguen, Guillaume; Serrero, Mélanie; Elgharabawy, Yasmine; Peyrin-Biroulet, Laurent.
Afiliação
  • Guillo L; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France.
  • Savoye G; Department of Gastroenterology, Rouen University Hospital, Rouen, France.
  • Amiot A; Department of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP, EC2M3-EA7375, University of Paris Est Créteil, Créteil, France.
  • Gilletta C; Department of Gastroenterology, Toulouse University Hospital, Toulouse, France.
  • Nachury M; Université de Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Dib N; Hepato-Gastroenterology Department, Angers University Hospital, Angers, France, HIFIH Laboratory, UPRES 3859, SFR 4208, Angers University, Angers, France.
  • Bourreille A; Department of Gastroenterology, Institut des Maladies de l'Appareil Digestif (IMAD), CIC Inserm 1413, Nantes University Hospital, Nantes, France.
  • Roblin X; Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Etienne, France.
  • Caillo L; Department of Gastroenterology, University Hospital of Nimes, Nimes, France.
  • Allez M; Department of Gastroenterology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, INSERM U1160, Université Paris Cité, Paris, France.
  • Picon L; Department of Gastroenterology, Tours University Hospital, Tours, France.
  • Hébuterne X; Gastroenterology and Clinical Nutrition, CHU of Nice, University Côte d'Azur, Nice, France.
  • Seksik P; Department of Gastroenterology, Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM, APHP, Hôpital Saint-Antoine, Paris, France.
  • Chupin A; Department of Gastroenterology, Georges-Pompidou European Hospital, Paris, France.
  • Buisson A; Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
  • Brixi H; Department of Gastroenterology, Reims University Hospital, Reims, France.
  • Altwegg R; Department of Gastroenterology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.
  • Simon M; Department of Gastroenterology, Institut Mutualiste Montsouris, Paris, France.
  • Amil M; Departement of Gastroenterology, Les Oudairies Hospital, La Roche-sur-Yon, France.
  • Laharie D; CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-Gastroentérologie et Oncologie Digestive, Université de Bordeaux, Bordeaux, France.
  • Bouguen G; Department of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.
  • Serrero M; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France.
  • Elgharabawy Y; Groupe d'étude Thérapeutique des Affections Inflammatoire du Tube digestive (GETAID), Paris, France.
  • Peyrin-Biroulet L; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Clin Transl Gastroenterol ; 14(12): e00607, 2023 12 01.
Article em En | MEDLINE | ID: mdl-37523417
ABSTRACT

INTRODUCTION:

Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort.

METHODS:

We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire.

RESULTS:

A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31-54). The median disease duration was 11 years (1-18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission.

DISCUSSION:

One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Doença de Crohn Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Doença de Crohn Idioma: En Ano de publicação: 2023 Tipo de documento: Article